# Penumbra Inc. (PEN) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Medical Devices & Supplies. Price $320.02, market value $12.6 billion.

## Valuation
- **P/E (trailing): 80.6×** (5-yr avg 722.3×, 3-yr avg 279.0×). Penumbra Inc. trades at 80.6× trailing earnings, well below its own five-year average of 722.3×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 51.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.04**. A PEG of 0.04 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 8.1×**. Each dollar of revenue is priced at 8.1×.
- **Price / book: 8.0×**. The shares trade at 8.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 1.6%** (5-yr avg 0.6%). Free cash flow equals 1.6% of the market value, above its five-year average of 0.6%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 1.2%**. The inverse of the P/E: 1.2% of the price is earned each year.

## Profitability
- **Gross margin: 68.0%**. Penumbra Inc. keeps 68.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 12.1%**. 12.1% of revenue is left after running the business.
- **Net margin: 12.7%**. 12.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.4%**. 12.4% on shareholders' equity is solid.
- **Return on assets: 8.6%**. Each dollar of assets produces 8.6% of profit.

## Growth
- **Revenue growth (1 yr): 17.5%** (3-yr 18.3%/yr, 5-yr 20.2%/yr). Revenue grew 17.5% over the last year, against 20.2% a year compounded over five years.
- **EPS growth (1 yr): 1155.6%**. Earnings per share rose 1155.6%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 6.64** (quick 6.64). Current assets cover the next year's liabilities 6.64 times.
- **Altman Z-score: 21.86**. A Z-score of 21.86 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Penumbra Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (13 analysts). 13 analysts cover Penumbra Inc.; the consensus is hold, with an average price target of $362.54 (+13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 41.3%** (YTD 3.4%, 3-mo -0.5%). The shares are up 41.3% over twelve months including dividends.
- **From 52-week high: -11.7%** (41.9% above the low). Trading 12% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 0.02** (volatility 27%). Beta of 0.02 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PEN · Page: https://foliofundamentals.com/stocks/pen

Not investment advice.